Skip to Main Content

Biotech investors are having some not-so-happy holidays.

In the last few months, several major funds have reportedly seen double-digit drops in their biotech portfolios’ value — leading some to wonder if the sector’s remarkable run is really, finally over this time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment